MapLight Therapeutics, Inc. 4

Catalyst4, Inc. purchased an aggregate 1,209,225 shares of MapLight Therapeutics, Inc. Voting Common Stock in the open market over July 28–30, 2026 for about $14.2 million, raising its indirect holdings to 20.9 million shares.

On July 28–30, 2026, Catalyst4, Inc., a significant insider of MapLight Therapeutics, Inc., executed a series of open‑market purchases of Voting Common Stock, acquiring 141,088 shares at a weighted average price of $10.7416, 65,137 shares at $11.6891, 3,000 shares at $12.63, and a large block of 1,000,000 shares at $13.00. These trades, executed in multiple transactions within the indicated price ranges, increased Catalyst4’s indirect beneficial ownership to 20,906,689 shares, with voting and dispositive power shared among Catalyst4’s directors Robert Brown, Ekemini Riley and Mark Vorsatz, each of whom disclaims beneficial ownership. Using the reported average prices, the total consideration for these four purchases is approximately $14.2 million, and the post‑transaction stake is valued at roughly $262–$272 million based on the most recent purchase prices.

Filing Facts

CIK

1770069

Ticker

MPLT

Form

4

Source Type

fda

Accession

0001900201-26-000003

Alert Tier

8